Mechanistic Role of the Calcium-Dependent Protease Calpain in the Endothelial Dysfunction Induced by MPO (Myeloperoxidase)

MPO (myeloperoxidase) is a peroxidase enzyme secreted by activated leukocytes that plays a pathogenic role in cardiovascular disease, mainly by initiating endothelial dysfunction. The molecular mechanisms of the endothelial damaging action of MPO remain though largely elusive. Calpain is a calcium-d...

Full description

Saved in:
Bibliographic Details
Published inHypertension (Dallas, Tex. 1979) Vol. 71; no. 4; pp. 761 - 770
Main Authors Etwebi, Zienab, Landesberg, Gavin, Preston, Kyle, Eguchi, Satoru, Scalia, Rosario
Format Journal Article
LanguageEnglish
Published United States American Heart Association, Inc 01.04.2018
Subjects
Online AccessGet full text

Cover

Loading…
Abstract MPO (myeloperoxidase) is a peroxidase enzyme secreted by activated leukocytes that plays a pathogenic role in cardiovascular disease, mainly by initiating endothelial dysfunction. The molecular mechanisms of the endothelial damaging action of MPO remain though largely elusive. Calpain is a calcium-dependent protease expressed in the vascular wall. Activation of calpains has been implicated in inflammatory disorders of the vasculature. Using endothelial cells and genetically modified mice, this study identifies the µ-calpain isoform as novel downstream signaling target of MPO in endothelial dysfunction. Mouse lung microvascular endothelial cells were stimulated with 10 nmol/L MPO for 180 minutes. MPO denitrosylated µ-calpain C-terminus domain, and time dependently activated µ-calpain, but not the m-calpain isoform. MPO also reduced Thr AMPK (AMP-activated protein kinase) and Ser eNOS (endothelial nitric oxide synthase) phosphorylation via upregulation of PP2A (protein phosphatase 2) expression. At the functional level, MPO increased endothelial VCAM-1 (vascular cell adhesion molecule 1) abundance and the adhesion of leukocytes to the mouse aorta. In MPO-treated endothelial cells, pharmacological inhibition of calpain activity attenuated expression of VCAM-1 and PP2A, and restored Thr AMPK and Ser eNOS phosphorylation. Compared with wild-type mice, µ-calpain deficient mice experienced reduced leukocyte adhesion to the aortic endothelium in response to MPO. Our data first establish a role for calpain in the endothelial dysfunction and vascular inflammation of MPO. The MPO/calpain/PP2A signaling pathway may provide novel pharmacological targets for the treatment of inflammatory vascular disorders.
AbstractList MPO (myeloperoxidase) is a peroxidase enzyme secreted by activated leukocytes that plays a pathogenic role in cardiovascular disease, mainly by initiating endothelial dysfunction. The molecular mechanisms of the endothelial damaging action of MPO remain though largely elusive. Calpain is a calcium-dependent protease expressed in the vascular wall. Activation of calpains has been implicated in inflammatory disorders of the vasculature. Using endothelial cells and genetically modified mice, this study identifies the µ-calpain isoform as novel downstream signaling target of MPO in endothelial dysfunction. Mouse lung microvascular endothelial cells were stimulated with 10 nmol/L MPO for 180 minutes. MPO denitrosylated µ-calpain C-terminus domain, and time dependently activated µ-calpain, but not the m-calpain isoform. MPO also reduced Thr172 AMPK (AMP-activated protein kinase) and Ser1177 eNOS (endothelial nitric oxide synthase) phosphorylation via upregulation of PP2A (protein phosphatase 2) expression. At the functional level, MPO increased endothelial VCAM-1 (vascular cell adhesion molecule 1) abundance and the adhesion of leukocytes to the mouse aorta. In MPO-treated endothelial cells, pharmacological inhibition of calpain activity attenuated expression of VCAM-1 and PP2A, and restored Thr172 AMPK and Ser1177 eNOS phosphorylation. Compared with wild-type mice, µ-calpain deficient mice experienced reduced leukocyte adhesion to the aortic endothelium in response to MPO. Our data first establish a role for calpain in the endothelial dysfunction and vascular inflammation of MPO. The MPO/calpain/PP2A signaling pathway may provide novel pharmacological targets for the treatment of inflammatory vascular disorders.
MPO (myeloperoxidase) is a peroxidase enzyme secreted by activated leukocytes that plays a pathogenic role in cardiovascular disease, mainly by initiating endothelial dysfunction. The molecular mechanisms of the endothelial damaging action of MPO remain though largely elusive. Calpain is a calcium-dependent protease expressed in the vascular wall. Activation of calpains has been implicated in inflammatory disorders of the vasculature. Using endothelial cells and genetically modified mice, this study identifies the µ-calpain isoform as novel downstream signaling target of MPO in endothelial dysfunction. Mouse lung microvascular endothelial cells were stimulated with 10 nmol/L MPO for 180 minutes. MPO denitrosylated µ-calpain C-terminus domain, and time dependently activated µ-calpain, but not the m-calpain isoform. MPO also reduced Thr AMPK (AMP-activated protein kinase) and Ser eNOS (endothelial nitric oxide synthase) phosphorylation via upregulation of PP2A (protein phosphatase 2) expression. At the functional level, MPO increased endothelial VCAM-1 (vascular cell adhesion molecule 1) abundance and the adhesion of leukocytes to the mouse aorta. In MPO-treated endothelial cells, pharmacological inhibition of calpain activity attenuated expression of VCAM-1 and PP2A, and restored Thr AMPK and Ser eNOS phosphorylation. Compared with wild-type mice, µ-calpain deficient mice experienced reduced leukocyte adhesion to the aortic endothelium in response to MPO. Our data first establish a role for calpain in the endothelial dysfunction and vascular inflammation of MPO. The MPO/calpain/PP2A signaling pathway may provide novel pharmacological targets for the treatment of inflammatory vascular disorders.
MPO (myeloperoxidase) is a peroxidase enzyme secreted by activated leukocytes that plays a pathogenic role in cardiovascular disease, mainly by initiating endothelial dysfunction. The molecular mechanisms of the endothelial damaging action of MPO remain though largely elusive. Calpain is a calcium-dependent protease expressed in the vascular wall. Activation of calpains has been implicated in inflammatory disorders of the vasculature. Using endothelial cells and genetically modified mice, this study identifies the µ-calpain isoform as novel downstream signaling target of MPO in endothelial dysfunction. Mouse lung microvascular endothelial cells were stimulated with 10 nmol/L MPO for 180 minutes. MPO denitrosylated µ-calpain C-terminus domain, and time dependently activated µ-calpain, but not the m-calpain isoform. MPO also reduced Thr 172 AMPK (AMP-activated protein kinase) and Ser 1177 eNOS (endothelial nitric oxide synthase) phosphorylation via upregulation of PP2A (protein phosphatase 2) expression. At the functional level, MPO increased endothelial VCAM-1 (vascular cell adhesion molecule 1) abundance and the adhesion of leukocytes to the mouse aorta. In MPO-treated endothelial cells, pharmacological inhibition of calpain activity attenuated expression of VCAM-1 and PP2A, and restored Thr 172 AMPK and Ser 1177 eNOS phosphorylation. Compared with wild-type mice, µ-calpain deficient mice experienced reduced leukocyte adhesion to the aortic endothelium in response to MPO. Our data first establish a role for calpain in the endothelial dysfunction and vascular inflammation of MPO. The MPO/calpain/PP2A signaling pathway may provide novel pharmacological targets for the treatment of inflammatory vascular disorders.
MPO (myeloperoxidase) is a peroxidase enzyme secreted by activated leukocytes that plays a pathogenic role in cardiovascular disease, mainly by initiating endothelial dysfunction. The molecular mechanisms of the endothelial damaging action of MPO remain though largely elusive. Calpain is a calcium-dependent protease expressed in the vascular wall. Activation of calpains has been implicated in inflammatory disorders of the vasculature. Using endothelial cells and genetically modified mice, this study identifies the µ-calpain isoform as novel downstream signaling target of MPO in endothelial dysfunction. Mouse lung microvascular endothelial cells were stimulated with 10 nmol/L MPO for 180 minutes. MPO denitrosylated µ-calpain C-terminus domain, and time dependently activated µ-calpain, but not the m-calpain isoform. MPO also reduced Thr AMPK (AMP-activated protein kinase) and Ser eNOS (endothelial nitric oxide synthase) phosphorylation via upregulation of PP2A (protein phosphatase 2) expression. At the functional level, MPO increased endothelial VCAM-1 (vascular cell adhesion molecule 1) abundance and the adhesion of leukocytes to the mouse aorta. In MPO-treated endothelial cells, pharmacological inhibition of calpain activity attenuated expression of VCAM-1 and PP2A, and restored Thr AMPK and Ser eNOS phosphorylation. Compared with wild-type mice, µ-calpain deficient mice experienced reduced leukocyte adhesion to the aortic endothelium in response to MPO. Our data first establish a role for calpain in the endothelial dysfunction and vascular inflammation of MPO. The MPO/calpain/PP2A signaling pathway may provide novel pharmacological targets for the treatment of inflammatory vascular disorders.
Author Scalia, Rosario
Preston, Kyle
Eguchi, Satoru
Etwebi, Zienab
Landesberg, Gavin
AuthorAffiliation From the Department of Physiology and the Cardiovascular Research Center, Temple University, Philadelphia, PA
AuthorAffiliation_xml – name: From the Department of Physiology and the Cardiovascular Research Center, Temple University, Philadelphia, PA
Author_xml – sequence: 1
  givenname: Zienab
  surname: Etwebi
  fullname: Etwebi, Zienab
  organization: From the Department of Physiology and the Cardiovascular Research Center, Temple University, Philadelphia, PA
– sequence: 2
  givenname: Gavin
  surname: Landesberg
  fullname: Landesberg, Gavin
– sequence: 3
  givenname: Kyle
  surname: Preston
  fullname: Preston, Kyle
– sequence: 4
  givenname: Satoru
  surname: Eguchi
  fullname: Eguchi, Satoru
– sequence: 5
  givenname: Rosario
  surname: Scalia
  fullname: Scalia, Rosario
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29507101$$D View this record in MEDLINE/PubMed
BookMark eNqNkE9vEzEQxS1URNPCV0DmVg5bPGt7_xw4RGkgkZomKkWC08przyoLjr1d76qkn75uUzhwQFi2Rn7-vRn5nZAj5x0S8g7YOUAGHxbfN_Prm_nVl-X6arqYRjE_B8aZfEEmIFORCJnxIzJhUIqkBPh2TE5C-MEYCCHyV-Q4LSXLgcGE3K9Qb5Vrw9Bqeu0tUt_QYYt0pqxux11ygR06g26gm94PqMLTU6daR-N-JOfO-Fhtqyy92IdmdHpovaNLZ0aNhtZ7utqs6dlqj9Z32PtfrYlt3r8mLxtlA755rqfk66f5zWyRXK4_L2fTy0SLLJcJoBElL2qtoCyKtFaywFpywDSqSnANtVQouWSGZ4UxmaxlnkOT1Zg2eV3yU3J26Nv1_nbEMFS7Nmi0Vjn0Y6hSBpBmZSlERMsDqnsfQo9N1fXtTvX7Clj1GH31V_RRzKun6KP37fOYsd6h-eP8nXUEPh6AO28H7MNPO95hX21R2WH7XwPEP_wsLpFmRRK_UzARb0k8nPMHqRWnBA
CitedBy_id crossref_primary_10_1161_HYPERTENSIONAHA_118_10441
crossref_primary_10_3389_fphar_2022_920977
crossref_primary_10_1038_s41586_019_1688_z
crossref_primary_10_1161_HYPERTENSIONAHA_120_15200
crossref_primary_10_3390_antiox11050874
crossref_primary_10_1016_j_bbrc_2019_06_063
crossref_primary_10_1089_vim_2022_0007
crossref_primary_10_1186_s12967_021_03022_x
crossref_primary_10_1016_j_ejphar_2022_174940
crossref_primary_10_2478_prolas_2023_0005
crossref_primary_10_1038_s41467_022_34910_5
crossref_primary_10_3389_fcvm_2021_745009
crossref_primary_10_1186_s12885_020_07058_y
crossref_primary_10_1016_j_ajpath_2021_06_006
crossref_primary_10_1016_j_pharmthera_2020_107685
crossref_primary_10_3390_antiox13010132
crossref_primary_10_1016_j_lfs_2023_121867
crossref_primary_10_1016_j_jgr_2022_07_006
crossref_primary_10_1016_j_pharmthera_2020_107711
crossref_primary_10_3389_fphys_2020_566410
crossref_primary_10_14814_phy2_15411
crossref_primary_10_1016_j_pharmthera_2020_107715
crossref_primary_10_1161_ATVBAHA_119_312725
crossref_primary_10_1089_ars_2020_8030
crossref_primary_10_1016_j_intimp_2023_110803
crossref_primary_10_1016_j_bbrc_2024_149681
crossref_primary_10_1089_ars_2018_7607
crossref_primary_10_1161_ATVBAHA_120_315452
Cites_doi 10.1161/CIRCULATIONAHA.112.000682
10.1016/S0002-9440(10)64845-6
10.4049/jimmunol.170.1.287
10.1007/s13577-012-0042-7
10.1016/j.jvs.2005.01.013
10.1161/01.RES.76.1.30
10.1016/j.amjmed.2003.10.025
10.1111/j.1742-4658.2008.06394.x
10.1016/j.freeradbiomed.2011.12.001
10.1161/01.CIR.0000140262.20831.8F
10.2337/diabetes.54.4.1132
10.1111/j.1432-1033.1995.tb20498.x
10.2337/diabetes.53.11.2950
10.1152/physrev.00029.2002
10.1161/01.ATV.0000250932.24151.50
10.1152/ajpcell.2000.279.3.C806
10.1073/pnas.2435008100
10.1038/sj.emboj.7600110
10.1161/HYPERTENSIONAHA.116.08854
10.1111/eci.12564
10.1186/s40478-017-0431-y
10.1126/science.1106830
10.1016/j.redox.2017.02.022
10.1016/j.biochi.2010.03.020
10.1016/j.bbrc.2017.01.132
10.1152/ajpendo.00510.2005
10.1111/j.1432-1033.1989.tb15186.x
10.1074/jbc.M211926200
10.1111/j.1600-6143.2005.01077.x
10.2337/db14-0784
10.1182/blood-2010-05-284513
10.1111/j.1742-4658.2007.06133.x
10.1016/j.cmet.2010.03.013
10.1186/s13104-015-1677-8
10.1038/21218
10.4049/jimmunol.163.6.3441
10.1001/jama.286.17.2136
10.1177/1933719114557899
10.1080/13510002.2016.1256119
10.1371/journal.pone.0151960
10.1084/jem.20041315
10.1016/S0014-5793(98)01705-0
10.1083/jcb.200206089
10.1002/1873-3468.12617
10.1172/JCI118074
10.1161/CIRCRESAHA.110.229393
10.1074/jbc.M608310200
10.1006/bbrc.1995.1285
10.1002/(SICI)1097-4644(19970801)66:2<197::AID-JCB7>3.0.CO;2-L
10.1097/01.shk.0000095056.62263.b2
10.1172/JCI118018
10.1016/j.freeradbiomed.2008.09.034
10.1093/aje/154.8.758
10.4049/jimmunol.1300972
10.1074/jbc.275.9.6123
10.1152/ajplung.2000.278.6.L1204
10.1096/fj.99-0645com
10.1038/33934
10.1016/j.foodchem.2016.06.104
10.1016/j.niox.2005.04.002
10.1182/blood-2003-08-2974
10.1096/fj.02-1213fje
10.1016/j.tem.2012.10.008
10.1074/jbc.M212831200
10.1016/j.freeradbiomed.2004.06.003
10.1074/jbc.M803638200
ContentType Journal Article
Copyright 2018 American Heart Association, Inc
2018 American Heart Association, Inc.
Copyright_xml – notice: 2018 American Heart Association, Inc
– notice: 2018 American Heart Association, Inc.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1161/HYPERTENSIONAHA.117.10305
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

CrossRef

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1524-4563
EndPage 770
ExternalDocumentID 10_1161_HYPERTENSIONAHA_117_10305
29507101
10.1161/HYPERTENSIONAHA.117.10305
00004268-201804000-00033
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: R01 HL133248
– fundername: NIDDK NIH HHS
  grantid: R01 DK064344
– fundername: NHLBI NIH HHS
  grantid: R01 HL128324
– fundername: NIDDK NIH HHS
  grantid: R01 DK111042
– fundername: NIDDK NIH HHS
  grantid: R01 DK096521
GroupedDBID -
.XZ
.Z2
01R
08R
0R
1J1
2WC
3O-
40H
4Q1
4Q2
4Q3
53G
55
5GY
5RE
5VS
71W
77Y
7O
7O~
AAAXR
AAMOA
AAMTA
AAPBV
AARTV
AAXQO
AAYEP
ABBUW
ABFLS
ABOCM
ABXVJ
ABZAD
ACDDN
ACEWG
ACGFS
ACWDW
ACWRI
ACXNZ
ADBBV
ADFPA
ADNKB
AE3
AENEX
AFFNX
AFUWQ
AHMBA
AHULI
AHVBC
AIJEX
AJIOK
AJNYG
AJYGW
ALMA_UNASSIGNED_HOLDINGS
AMJPA
ASCII
AWKKM
BAWUL
BOYCO
BQLVK
C1A
C45
CS3
DIK
DUNZO
E.X
E3Z
EBS
EJD
EX3
F2K
F2L
F2M
F2N
F5P
FL-
FW0
GJ
GX1
H0
H0~
H13
HZ
IKYAY
IN
IN~
JF9
JG8
JK3
JK8
K8S
KD2
KMI
KQ8
L-C
L7B
LI0
N9A
N~7
N~B
N~M
O0-
O9-
OAG
OAH
OB3
OCUKA
ODA
OGROG
OHASI
OK1
OL1
OLG
OLH
OLU
OLV
OLW
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OWW
OWY
OXXIT
P-K
P2P
PQEST
PQQKQ
R58
RAH
RHF
RIG
RLZ
RSW
S4R
S4S
V2I
WH7
WOQ
WOW
X3V
X3W
X7M
XZ
YHZ
Z2
ZA5
ZGI
---
.-D
.3C
.55
.GJ
0R~
18M
AAAAV
AAFWJ
AAGIX
AAHPQ
AAIQE
AAJCS
AAQKA
AASCR
AASOK
ABASU
ABDIG
ABJNI
ABQRW
ABVCZ
ACCJW
ACGFO
ACILI
ACLDA
ACXJB
ADGGA
ADHPY
AE6
AEBDS
AEETU
AFDTB
AFEXH
AGINI
AHOMT
AHQNM
AHRYX
AINUH
AJNWD
AJZMW
AKULP
ALMTX
AMKUR
AMNEI
AOHHW
BCGUY
BS7
CGR
CUY
CVF
DIWNM
ECM
EEVPB
EIF
ERAAH
FCALG
GNXGY
GQDEL
HLJTE
HZ~
IKREB
IPNFZ
K-A
K-F
N4W
NPM
ODMTH
OHYEH
OWBYB
OWU
OWV
OWX
OWZ
T8P
TEORI
TR2
TSPGW
VVN
W3M
W8F
XXN
XYM
YFH
YOC
YYM
YYP
ZFV
ZZMQN
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c4675-1ed4938bca19882ba58eb531e2938a43c1b5ae5350d368dd65b5771f6be2f7b93
ISSN 0194-911X
IngestDate Fri Aug 16 08:44:06 EDT 2024
Fri Aug 23 00:39:07 EDT 2024
Wed Oct 16 00:50:53 EDT 2024
Thu Aug 13 19:44:27 EDT 2020
Thu Aug 13 19:52:28 EDT 2020
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords calpain
cell adhesion molecules
endothelial cells
inflammation
peroxidase
Language English
License 2018 American Heart Association, Inc.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c4675-1ed4938bca19882ba58eb531e2938a43c1b5ae5350d368dd65b5771f6be2f7b93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ahajournals.org/doi/pdf/10.1161/HYPERTENSIONAHA.117.10305
PMID 29507101
PQID 2011269944
PQPubID 23479
PageCount 10
ParticipantIDs proquest_miscellaneous_2011269944
crossref_primary_10_1161_HYPERTENSIONAHA_117_10305
pubmed_primary_29507101
wolterskluwer_health_10_1161_HYPERTENSIONAHA_117_10305
wolterskluwer_health_00004268-201804000-00033
ProviderPackageCode L-C
C45
7O~
AARTV
ADFPA
OLH
ASCII
OLG
AAMOA
ODA
ABZAD
ABBUW
JK3
ADNKB
JK8
H0~
1J1
OLV
OLU
JG8
OLW
OLZ
OLY
F2K
F2M
F2L
F2N
OHASI
AHVBC
AJNYG
FL-
KMI
K8S
OGROG
OVLEI
AJIOK
OPUJH
V2I
.XZ
S4R
S4S
4Q1
DUNZO
OAG
4Q2
OVDNE
4Q3
AMJPA
OAH
OVD
71W
AHULI
ACEWG
OB3
.Z2
N~7
IKYAY
OVIDH
AWKKM
40H
N~B
OUVQU
ORVUJ
X3V
X3W
ACDDN
ACWRI
BOYCO
AIJEX
AAXQO
AAMTA
AAAXR
E.X
OWW
OCUKA
OWY
01R
ACXNZ
OL1
ABXVJ
IN~
KD2
OXXIT
77Y
ACWDW
JF9
FW0
PublicationCentury 2000
PublicationDate 2018-April
PublicationDateYYYYMMDD 2018-04-01
PublicationDate_xml – month: 04
  year: 2018
  text: 2018-April
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Hypertension (Dallas, Tex. 1979)
PublicationTitleAlternate Hypertension
PublicationYear 2018
Publisher American Heart Association, Inc
Publisher_xml – name: American Heart Association, Inc
References 29507102 - Hypertension. 2018 Apr;71(4):574-576
e_1_3_3_50_2
e_1_3_3_16_2
e_1_3_3_18_2
e_1_3_3_39_2
e_1_3_3_12_2
e_1_3_3_37_2
e_1_3_3_58_2
e_1_3_3_14_2
e_1_3_3_35_2
e_1_3_3_56_2
e_1_3_3_33_2
e_1_3_3_54_2
e_1_3_3_10_2
e_1_3_3_31_2
e_1_3_3_52_2
e_1_3_3_40_2
e_1_3_3_61_2
e_1_3_3_5_2
e_1_3_3_7_2
e_1_3_3_9_2
e_1_3_3_27_2
e_1_3_3_29_2
e_1_3_3_23_2
e_1_3_3_48_2
e_1_3_3_25_2
e_1_3_3_46_2
e_1_3_3_67_2
e_1_3_3_44_2
e_1_3_3_65_2
e_1_3_3_3_2
e_1_3_3_21_2
e_1_3_3_42_2
e_1_3_3_63_2
Cunha FQ (e_1_3_3_51_2) 1994; 81
e_1_3_3_17_2
e_1_3_3_19_2
e_1_3_3_38_2
e_1_3_3_13_2
e_1_3_3_36_2
e_1_3_3_59_2
e_1_3_3_15_2
e_1_3_3_34_2
e_1_3_3_57_2
e_1_3_3_32_2
e_1_3_3_55_2
e_1_3_3_11_2
e_1_3_3_30_2
e_1_3_3_53_2
e_1_3_3_62_2
e_1_3_3_60_2
e_1_3_3_6_2
e_1_3_3_8_2
e_1_3_3_28_2
e_1_3_3_49_2
e_1_3_3_24_2
e_1_3_3_47_2
e_1_3_3_26_2
e_1_3_3_45_2
e_1_3_3_68_2
e_1_3_3_2_2
e_1_3_3_20_2
e_1_3_3_43_2
e_1_3_3_66_2
e_1_3_3_4_2
e_1_3_3_22_2
e_1_3_3_41_2
e_1_3_3_64_2
References_xml – ident: e_1_3_3_3_2
  doi: 10.1161/CIRCULATIONAHA.112.000682
– ident: e_1_3_3_37_2
  doi: 10.1016/S0002-9440(10)64845-6
– ident: e_1_3_3_47_2
  doi: 10.4049/jimmunol.170.1.287
– ident: e_1_3_3_63_2
  doi: 10.1007/s13577-012-0042-7
– ident: e_1_3_3_4_2
  doi: 10.1016/j.jvs.2005.01.013
– ident: e_1_3_3_60_2
  doi: 10.1161/01.RES.76.1.30
– ident: e_1_3_3_11_2
  doi: 10.1016/j.amjmed.2003.10.025
– ident: e_1_3_3_53_2
  doi: 10.1111/j.1742-4658.2008.06394.x
– ident: e_1_3_3_54_2
  doi: 10.1016/j.freeradbiomed.2011.12.001
– ident: e_1_3_3_6_2
  doi: 10.1161/01.CIR.0000140262.20831.8F
– ident: e_1_3_3_18_2
  doi: 10.2337/diabetes.54.4.1132
– ident: e_1_3_3_42_2
  doi: 10.1111/j.1432-1033.1995.tb20498.x
– ident: e_1_3_3_43_2
  doi: 10.2337/diabetes.53.11.2950
– ident: e_1_3_3_12_2
  doi: 10.1152/physrev.00029.2002
– ident: e_1_3_3_35_2
  doi: 10.1161/01.ATV.0000250932.24151.50
– ident: e_1_3_3_48_2
  doi: 10.1152/ajpcell.2000.279.3.C806
– ident: e_1_3_3_49_2
  doi: 10.1073/pnas.2435008100
– ident: e_1_3_3_28_2
  doi: 10.1038/sj.emboj.7600110
– ident: e_1_3_3_7_2
  doi: 10.1161/HYPERTENSIONAHA.116.08854
– ident: e_1_3_3_44_2
  doi: 10.1111/eci.12564
– ident: e_1_3_3_55_2
  doi: 10.1186/s40478-017-0431-y
– ident: e_1_3_3_33_2
  doi: 10.1126/science.1106830
– ident: e_1_3_3_34_2
  doi: 10.1016/j.redox.2017.02.022
– ident: e_1_3_3_40_2
  doi: 10.1016/j.biochi.2010.03.020
– ident: e_1_3_3_45_2
  doi: 10.1016/j.bbrc.2017.01.132
– ident: e_1_3_3_27_2
  doi: 10.1152/ajpendo.00510.2005
– ident: e_1_3_3_41_2
  doi: 10.1111/j.1432-1033.1989.tb15186.x
– ident: e_1_3_3_38_2
  doi: 10.1074/jbc.M211926200
– ident: e_1_3_3_68_2
  doi: 10.1111/j.1600-6143.2005.01077.x
– ident: e_1_3_3_36_2
  doi: 10.2337/db14-0784
– ident: e_1_3_3_62_2
  doi: 10.1182/blood-2010-05-284513
– ident: e_1_3_3_52_2
  doi: 10.1111/j.1742-4658.2007.06133.x
– ident: e_1_3_3_19_2
  doi: 10.1016/j.cmet.2010.03.013
– ident: e_1_3_3_21_2
  doi: 10.1186/s13104-015-1677-8
– ident: e_1_3_3_25_2
  doi: 10.1038/21218
– ident: e_1_3_3_32_2
  doi: 10.4049/jimmunol.163.6.3441
– ident: e_1_3_3_10_2
  doi: 10.1001/jama.286.17.2136
– ident: e_1_3_3_46_2
  doi: 10.1177/1933719114557899
– ident: e_1_3_3_8_2
  doi: 10.1080/13510002.2016.1256119
– ident: e_1_3_3_61_2
  doi: 10.1371/journal.pone.0151960
– ident: e_1_3_3_16_2
  doi: 10.1084/jem.20041315
– ident: e_1_3_3_26_2
  doi: 10.1016/S0014-5793(98)01705-0
– volume: 81
  start-page: 211
  year: 1994
  ident: e_1_3_3_51_2
  article-title: Differential induction of nitric oxide synthase in various organs of the mouse during endotoxaemia: role of TNF-alpha and IL-1-beta.
  publication-title: Immunology
  contributor:
    fullname: Cunha FQ
– ident: e_1_3_3_65_2
  doi: 10.1083/jcb.200206089
– ident: e_1_3_3_29_2
  doi: 10.1002/1873-3468.12617
– ident: e_1_3_3_31_2
  doi: 10.1172/JCI118074
– ident: e_1_3_3_67_2
  doi: 10.1161/CIRCRESAHA.110.229393
– ident: e_1_3_3_30_2
  doi: 10.1074/jbc.M608310200
– ident: e_1_3_3_22_2
  doi: 10.1006/bbrc.1995.1285
– ident: e_1_3_3_14_2
  doi: 10.1002/(SICI)1097-4644(19970801)66:2<197::AID-JCB7>3.0.CO;2-L
– ident: e_1_3_3_64_2
  doi: 10.1097/01.shk.0000095056.62263.b2
– ident: e_1_3_3_20_2
  doi: 10.1172/JCI118018
– ident: e_1_3_3_24_2
  doi: 10.1016/j.freeradbiomed.2008.09.034
– ident: e_1_3_3_5_2
  doi: 10.1093/aje/154.8.758
– ident: e_1_3_3_13_2
  doi: 10.4049/jimmunol.1300972
– ident: e_1_3_3_56_2
  doi: 10.1074/jbc.275.9.6123
– ident: e_1_3_3_57_2
  doi: 10.1152/ajplung.2000.278.6.L1204
– ident: e_1_3_3_17_2
  doi: 10.1096/fj.99-0645com
– ident: e_1_3_3_59_2
  doi: 10.1038/33934
– ident: e_1_3_3_23_2
  doi: 10.1016/j.foodchem.2016.06.104
– ident: e_1_3_3_50_2
  doi: 10.1016/j.niox.2005.04.002
– ident: e_1_3_3_66_2
  doi: 10.1182/blood-2003-08-2974
– ident: e_1_3_3_58_2
  doi: 10.1096/fj.02-1213fje
– ident: e_1_3_3_2_2
  doi: 10.1016/j.tem.2012.10.008
– ident: e_1_3_3_39_2
  doi: 10.1074/jbc.M212831200
– ident: e_1_3_3_9_2
  doi: 10.1016/j.freeradbiomed.2004.06.003
– ident: e_1_3_3_15_2
  doi: 10.1074/jbc.M803638200
SSID ssj0014447
Score 2.451012
Snippet MPO (myeloperoxidase) is a peroxidase enzyme secreted by activated leukocytes that plays a pathogenic role in cardiovascular disease, mainly by initiating...
SourceID proquest
crossref
pubmed
wolterskluwer
SourceType Aggregation Database
Index Database
Publisher
StartPage 761
SubjectTerms Animals
Animals, Genetically Modified
Aorta - metabolism
Aorta - pathology
Calpain - metabolism
Cell Adhesion - physiology
Cell Adhesion Molecules - metabolism
Cell Culture Techniques
Endothelial Cells - immunology
Endothelial Cells - metabolism
Inflammation - immunology
Leukocytes - physiology
Mice
Peroxidase - metabolism
Protein Phosphatase 2 - metabolism
Signal Transduction
Up-Regulation
Vascular Diseases - immunology
Vascular Diseases - metabolism
Title Mechanistic Role of the Calcium-Dependent Protease Calpain in the Endothelial Dysfunction Induced by MPO (Myeloperoxidase)
URI http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004268-201804000-00033
https://www.ncbi.nlm.nih.gov/pubmed/29507101
https://search.proquest.com/docview/2011269944
Volume 71
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZB2VjjN2X3VBhDxvFrWX5psfQuA1bk5aRQLYXY9nKCMvikjhb03-xf7xzZMVxm451g2CCI4Tx-XJu-s45hLx1FRhFW3lW5nAOAQoLLZkFNra7A8Sk4HArrHfu9vzOwP0w9IaNxq8aa2lRyL304tq6kv-RKtwDuWKV7D9IttoUbsB3kC9cQcJwvZGMuwrrdnWr5d1PhiaIjuRBMknHi-9W20y4LbAeoMCDGPzpLBlX9MZommEJ1gTz5u3lHK2cBgRO9EhL57R7eoJuaHeJ5CI1y8_HWTKvejkZv7YD4exMk-E1msI25udLBpI639tlIhC1nENUgPLWNIIvoFkSWbGCMKM9XzHOjpIf4wq6SBUxTP-Py0mFxugrDnMpU9tFPlvUkxgAiDX3RRnF67gWOHO8rpnL4SwGgW5NzQY-q1nsoBw9smkMfDQGnc-nEYQGPbRNrU4LT6mx04DtrS3g6tS_dxIfDo6P43407N8it51AeMgSPRpWrCEIP91gm-yY7ff_uPllN2cjdrlL7v3MkQ4x_6arIWo-Tf8BuW-CEdoqkfWQNNT0EdnuGrrFY3JRAxhFgNF8RAEudANgdAUwagBG4YMrawCjNYBRAzAqlxQARt9dgdf7J2RwGPUPOpYZ1mGlYGs9i6nMFTyUacIERG0y8UIlQcEr8CfDxOUpk16iPO7ZGffDLPM96QUBG_lSOaNACv6UbE3zqXpOqMODkQRbI1PFXCVgoWLYF9ERUoF5EU3irN5tfFb2ZIl1LOuz-IpAsJd9rAXSJDsrKcSgQfFYLJmqfDGP0QV2fCFct0meleKptnUExks2axLrkrzisko51iG246NaYiHaQ92mgfMm8a9d_9fHfHGDx3xJ7qz_Q6_IVjFbqNfgGhfyjQbrb1NutmM
link.rule.ids 315,786,790,27955,27956
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mechanistic+Role+of+the+Calcium-Dependent+Protease+Calpain+in+the+Endothelial+Dysfunction+Induced+by+MPO+%28Myeloperoxidase%29&rft.jtitle=Hypertension+%28Dallas%2C+Tex.+1979%29&rft.au=Etwebi%2C+Zienab&rft.au=Landesberg%2C+Gavin&rft.au=Preston%2C+Kyle&rft.au=Eguchi%2C+Satoru&rft.date=2018-04-01&rft.eissn=1524-4563&rft.volume=71&rft.issue=4&rft.spage=761&rft.epage=770&rft_id=info:doi/10.1161%2FHYPERTENSIONAHA.117.10305&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0194-911X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0194-911X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0194-911X&client=summon